25,666 results match your criteria rituximab

Prolonged COVID-19 Disease in a Patient with Rheumatoid Arthritis on Rituximab Therapy.

J Infect Dis 2021 May 8. Epub 2021 May 8.

Division of Pulmonary, Critical Care, and Sleep Medicine. Department of Medicine. Northwell Health. New York, USA.

View Article and Full-Text PDF

Natural history of EBV replication and viral load dynamics after alemtuzumab based allogeneic stem cell transplantation.

Transplant Cell Ther 2021 May 4. Epub 2021 May 4.

Department of Haematology, UCL Cancer Institute, University College London, London, UK; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.

Background: Epstein-Barr virus (EBV) load monitoring post-allogeneic haematopoietic stem cell transplantation (HSCT) enables earlier detection of EBV replication and is often used as a trigger for pre-emptive therapies aiming to reduce EBV-related diseases. Our institutional strategy is to treat patients with clinical signs of EBV-related disease accompanied by a rising viral load, rather than to intervene solely based on viral load. This affords an opportunity to study the natural history of EBV replication and to assess if our strategy reduces over-treatment without compromising outcomes. Read More

View Article and Full-Text PDF

Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.

Blood Adv 2021 May;5(9):2426-2437

Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.

The dilemma of whether to treat elderly patients with diffuse large B-cell lymphoma (DLBCL) with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone+rituximab) is often faced by clinicians. We conducted a systematic review assessing the impact of R-CHOP DI on DLBCL survival outcomes, according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols (PRISMA-P) guidelines. We searched MEDLINE, EMBASE, and Cochrane CENTRAL for studies with ≥100 patients treated with R-CHOP/R-CHOP-like therapies published from January 2002 through November 2020. Read More

View Article and Full-Text PDF

Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.

Eur J Haematol 2021 May 7. Epub 2021 May 7.

Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

Background: Primary Central Nervous System Lymphoma (PCNSL) is a rare type of aggressive lymphoma of the central nervous system. Treatment strategies improved significantly over the past decades, differ regionally but mainly consist of rituximab and high-dosed methotrexate (MTX)-based therapies.

Methods: We assessed clinical outcomes of 100 patients with newly diagnosed PCNSL between 2010-2020 at the University Hospital of Cologne, Germany. Read More

View Article and Full-Text PDF

Serum sickness induced by alemtuzumab in a kidney-pancreas transplant recipient.

Clin Nephrol 2021 May 7. Epub 2021 May 7.

Serum sickness is an immune-complex-mediated hypersensitivity reaction that was first noted in the early 1900s in patients receiving heterologous antisera, such as horse antitetanus or antidiphtheria serum. This condition is primarily self-limited; however, in its acute state, it can cause severe symptoms of fever, rash, polyarthritis, or polyarthralgias. In solid organ transplantation, this condition is frequently reported in association with the use of rabbit anti-thymocyte globulin and chimeric murine monoclonal antibodies such as rituximab. Read More

View Article and Full-Text PDF

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Br J Haematol 2021 May 7. Epub 2021 May 7.

Department of Haematology, Oxford University Hospital NHS Foundation Trust, Oxford, UK.

Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line 'attenuated' or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenuated immunochemotherapy in 95 patients with MCL across 19 centres in the UK and Ireland considered unfit for full-dose rituximab-bendamustine or rituximab-cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP). Read More

View Article and Full-Text PDF

Infantile giant cell hepatitis with autoimmune hemolytic anemia.

World J Hepatol 2021 Apr;13(4):411-420

Department of Pediatrics, National Research Center for Maternal and Child Health, Nur-Sultan 010000, Kazakhstan.

Giant cell hepatitis (GCH) is characterized by large and multinucleated (syncytial) hepatocytes in the context of liver inflammation. Infantile GCH is typically associated with autoimmune hemolytic anemia in the absence of any other systemic or organ-specific autoimmune comorbidity. The etiology is unknown; concomitant viral infections (as potential trigger factors) have been identified in a few patients. Read More

View Article and Full-Text PDF

Current and emerging therapies for primary central nervous system lymphoma.

Biomark Res 2021 May 6;9(1):32. Epub 2021 May 6.

Department of Hematology, Huashan Hospital, Fudan University, 12 Wulumuqi Middle Road, Shanghai, 200040, China.

Primary central nervous system (CNS) lymphoma (PCNSL) is a rare type of extranodal lymphoma exclusively involving the CNS at the onset, with diffuse large B-cell lymphoma (DLBCL) as the most common histological subtype. As PCNSL is a malignancy arising in an immune-privileged site, suboptimal delivery of systemic agents into tumor tissues results in poorer outcomes in PCNSL than in non-CNS DLBCLs. Commonly used regimens for PCNSL include high-dose methotrexate-based chemotherapy with rituximab for induction therapy and intensive chemotherapy followed by autologous hematopoietic stem cell transplantation or whole-brain radiotherapy for consolidation therapy. Read More

View Article and Full-Text PDF

Identification of neutrophil β2-integrin LFA-1 as a potential mechanistic biomarker in ANCA-associated vasculitis via microarray and validation analyses.

Arthritis Res Ther 2021 May 6;23(1):136. Epub 2021 May 6.

Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan.

Background: Leukocyte activation by anti-neutrophil cytoplasmic antibody (ANCA) and the subsequent leukocyte-endothelium interaction play a key role in the development of endothelial damage in ANCA-associated vasculitis (AAV). In contrast to that of leukocyte activation, the exact role of the leukocyte-endothelium interaction via integrin remains unclear. Here, we performed microarray and validation analyses to explore association between the expression levels of lymphocyte function-associated antigen-1 (LFA-1) and the clinical characteristics of patients with AAV. Read More

View Article and Full-Text PDF

Transplant-associated thrombotic microangiopathy and immune haematological complications following intestine-containing organ transplantation: experience from over 100 consecutive cases.

Br J Haematol 2021 May 5. Epub 2021 May 5.

Department of Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Descriptions of passenger lymphocyte syndrome (PLS), immune cytopenias and transplant-associated thrombotic microangiopathy (TA-TMA) after intestine-containing transplants remain scarce. We describe our centre's experience of these complications from 2007 to 2019. Ninety-six patients received 103 transplants. Read More

View Article and Full-Text PDF

Rituximab Treatment in Acute Disseminated Encephalomyelitis Associated with Infection.

Case Rep Pediatr 2021 17;2021:5570566. Epub 2021 Apr 17.

Eskisehir Osmangazi University Faculty of Medicine, Pediatric Intensive Care Unit, Eskisehir, Turkey.

Acute disseminated encephalomyelitis (ADEM) is an inflammatory, demyelinating, and rapidly progressive disorder of the central nervous system. This condition is also known as postinfectious encephalomyelitis, and it is characterized by multifocal lesions in the brain and spinal cord with widespread neurological findings. High doses of intravenous (IV) methylprednisolone, intravenous immunoglobulin (IVIG), and plasma exchange (PLEX) treatments comprise the first-line therapy. Read More

View Article and Full-Text PDF

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.

Front Pharmacol 2021 19;12:644187. Epub 2021 Apr 19.

Department of Pharmaceutical and Pharmacological Sciences, Clinical Pharmacology and Pharmacotherapy, KU Leuven, Leuven, Belgium.

Best-value biological medicines may generate competition in the off-patent biologicals market, resulting in having more resources available to provide patients with access to necessary medicines while maintaining high-quality care. Belgium is a country known to have low biosimilar market shares, suggesting a malfunctioning market for off-patent biologicals. This study aims to gain an in-depth understanding of the Belgian off-patent biologicals market, by looking at the evolution in volumes and costs of the relevant products in the market. Read More

View Article and Full-Text PDF

Epstein-Barr virus induced haemophagocytic lymphohistiocytosis.

BMJ Case Rep 2021 May 5;14(5). Epub 2021 May 5.

Department of Hematology and Oncology, William Beaumont Hospital, Royal Oak, Michigan, USA.

Haemophagocytic lymphohistiocytosis (HLH) is a rare condition of uncontrolled immune activation as a result of an inherited genetic defect or in response to malignancy, autoimmune disease, rheumatological disease, AIDS infection or post-transplant immunosuppression. Described here is the case of a 19-year-old Caucasian man who presented with complaints of worsening fever, new-onset jaundice and lethargy after failing treatment for suspected infectious mononucleosis. Physical examination was significant for fever and splenomegaly while laboratory results revealed transaminitis, cytopaenia, indirect hyperbilirubinaemia and elevated ferritin, raising the likelihood of both autoimmune haemolytic anaemia and HLH. Read More

View Article and Full-Text PDF

Outcome of Surgical Resection and Chemotherapy Versus Chemotherapy Alone for the Treatment of Isolated Primary Adrenal Lymphoma: A Retrospective Cohort Study of 16 Consecutive Patients.

Anticancer Res 2021 May;41(5):2647-2652

Department of Surgery, Regina Elena Cancer Institute, Rome, Italy.

Background/aim: Primary adrenal lymphoma (PAL) is rare and aggressive. The aim of this retrospective study was to compare the results of surgery and chemotherapy compared to chemotherapy alone for the treatment of this condition.

Patients And Methods: Sixteen patients, 10 men and 6 women of a median age of 63 years (IQR=56-70. Read More

View Article and Full-Text PDF

Hematological involvement in pediatric systemic lupus erythematosus: A multi-center study.

Lupus 2021 May 6:9612033211014271. Epub 2021 May 6.

Division of Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Introduction: Systemic lupus erythematosus (SLE) may present with features of several systems, including hematological manifestations. In this study, we aimed to evaluate the characteristics of hematological involvement and assess possible associations and correlations in pediatric SLE patients.

Method: This is a retrospective multi-center study. Read More

View Article and Full-Text PDF

Fatal hemoperitoneum due to rupture of mesenteric artery in remission state of microscopic polyangiitis, concomitant with severe hypertension and posterior reversible encephalopathy syndrome: an autopsy case report.

CEN Case Rep 2021 May 4. Epub 2021 May 4.

Department of Pathology and Oncology, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan.

Microscopic polyangiitis (MPA) is a type of necrotizing vasculitis associated with high levels of myeloperoxidase-specific antineutrophil cytoplasmic antibody (MPO-ANCA). While generally associated with renal dysfunction, MPA can also cause intraabdominal hemorrhage in rare cases. A 66-year-old man was admitted to our hospital for renal dysfunction, numbness, and weight loss for 3 months. Read More

View Article and Full-Text PDF

Epidermolysis bullosa acquisita: an uncommon cause of esophageal stricture.

Oxf Med Case Reports 2021 Apr 28;2021(4):omab010. Epub 2021 Apr 28.

Division of Gastroenterology and Hepatology, Montefiore Medical Center, Bronx, NY, USA.

Epidermolysis bullosa acquisita (EBA) encompasses a wide spectrum of rare diseases with a common genetic origin transmitted in an autosomal recessive fashion. Mild forms of non-inflammatory EBA are characterized by skin lesions and have gained great relevance in the literature. However, resistant inflammatory EBA with widespread mucosal involvement remains a rare entity given its low prevalence. Read More

View Article and Full-Text PDF

Primary Vitreoretinal Lymphoma Therapy Monitoring: Significant Vitreous Haze Reduction After Intravitreal Rituximab.

Neurosignals 2021 05;29(S1):1-7

Department of Ophthalmology, Charité - University Medicine Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.

Background/aims: Intravitreal rituximab is an off-label treatment option for primary vitreoretinal lymphoma (PVRL). The objective of this study was to monitor the therapeutic response and safety profile of intravitreal rituximab in a cohort of PVRL patients.

Methods: In this retrospective, uncontrolled, open label, multicentre study, 20 eyes from 15 consecutive patients diagnosed with PRVL received at least one intravitreal injection of 1mg in 0. Read More

View Article and Full-Text PDF

"Indium-labelled autologous platelet sequestration studies predict response to splenectomy in immune thrombocytopenia: An Australian experience".

Intern Med J 2021 May 4. Epub 2021 May 4.

Consultant Haematologist Andrew Love Cancer Centre, University Hospital Geelong.

Background: Splenectomy is an effective intervention in primary immune thrombocytopenia (ITP). Attempts to define pre-clinical predictors of platelet response to splenectomy are inconsistent. Based on international studies defining the likelihood of platelet response using platelet sequestration, patients with relapsed/refractory ITP being considered for splenectomy at a regional Australian hospital were assessed with Indium-labelled autologous platelet sequestration (ILAPS) studies. Read More

View Article and Full-Text PDF

Multicentric Castleman's disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018.

Infection 2021 May 4. Epub 2021 May 4.

Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany.

Purpose: Castleman's disease (CD) is a well-established entity but there is a lack of available data regarding the management and therapy of HIV- and HHV-8-positive multicentric CD (MCD). We provide our own single-center experience with HIV-associated MCD.

Methods: We performed a retrospective, descriptive study on a cohort of patients with MCD, diagnosed and admitted to the infectious diseases or intensive care unit in the University Hospital Düsseldorf between 2008 and 2018. Read More

View Article and Full-Text PDF

Therapeutic options for cutaneous polyarteritis nodosa: a systematic review.

Rheumatology (Oxford) 2021 May 3. Epub 2021 May 3.

Department of Internal Medicine, Division of Rheumatology, University of Cyprus Medical School, Nicosia, Cyprus.

Objective: Cutaneous polyarteritis nodosa (CPAN) is a necrotizing vasculitis of the middle-size vessels, confined to the skin. We conducted a systematic review in order to identify studies evaluating the different treatment modalities used in CPAN.

Methods: This systematic review was conducted according to PRISMA guidelines, registered in PROSPERO: CRD42020222195. Read More

View Article and Full-Text PDF

Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients.

Blood Adv 2021 May;5(9):2375-2384

Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam UMC, Vrije Universeit Amsterdam, Amsterdam, The Netherlands.

Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. Read More

View Article and Full-Text PDF

Successful desensitization with chemotherapeutic drugs: a Tertiary Care Center Experience.

Eur Ann Allergy Clin Immunol 2021 May 4. Epub 2021 May 4.

Department of Chest Diseases, Division of Allergy and Clinical Immunology, Hacettepe University School of Medicine, Ankara, Turkey.

Summary: Hypersensitivity reactions to chemotherapeutic drugs are increasing all over the world, and desensitization to them has become the standard treatment approach. This study aimed to evaluate the characteristics of chemotherapeutic drug hypersensitivity reactions and the outcome of desensitization procedures. Between January 2017 and 2019, patients who have been desensitized to chemotherapeutic drugs were included retrospectively. Read More

View Article and Full-Text PDF

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.

Cancer Sci 2021 May 4. Epub 2021 May 4.

Department of Hematology and Oncology, Osaka University Hospital, Osaka, Japan.

Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent anti-mitotic agent (monomethyl auristatin E) to B-cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m , rituximab 375 mg/m (pola+BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Read More

View Article and Full-Text PDF

Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.

Hematol Oncol 2021 May 4. Epub 2021 May 4.

Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Germany.

Owing to its heterogeneity and rarity, management of disseminated marginal zone B-cell lymphoma (MZL) remains largely understudied. We present prospective data on choice of systemic treatment and survival of patients with MZL treated in German routine practice. Of 175 patients with MZL who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) collecting data on systemic treatment, 58 were classified as extranodal MZL of mucosa-associated lymphoid tissue (MALT) and 117 as non-MALT MZL. Read More

View Article and Full-Text PDF

Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib.

Br J Haematol 2021 May 3. Epub 2021 May 3.

National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

We assessed the concordance between immunohistochemistry (IHC) and gene expression profiling (GEP) for determining diffuse large B-cell lymphoma (DLBCL) cell of origin (COO) in the phase III PHOENIX trial of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without ibrutinib. Among 910 of 1114 screened patients with non-germinal centre B cell-like (non-GCB) DLBCL by IHC, the concordance with GEP for non-GCB calls was 82·7%, with 691 (75·9%) identified as activated B cell-like (ABC), and 62 (6·8%) as unclassified. Among 746 of 837 enrolled patients with verified non-GCB DLBCL by IHC, the concordance with GEP was 82·8%, with 567 (76·0%) identified as ABC and 51 (6·8%) unclassified; survival outcomes were similar regardless of COO or treatment, whereas among patients with ABC DLBCL aged <60 years, the overall and event-free survival were substantially better with ibrutinib versus placebo plus R-CHOP [hazard ratio (HR) 0·365, 95% confidence interval (CI) 0·147-0·909, P = 0·0305; HR 0·561, 95% CI 0·326-0·967, P = 0·0348, respectively]. Read More

View Article and Full-Text PDF

A prognostic immune risk score for diffuse large B-cell lymphoma.

Br J Haematol 2021 May 3. Epub 2021 May 3.

Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.

We constructed a prognostic score for persons with diffuse large B-cell lymphoma (DLBCL) based on infiltrating immune cells. Data of 956 consecutive subjects were retrieved from the Gene Expression Omnibus database and assigned to training (GSE10846, n = 305) or validation (GSE87371 n = 206 and GSE117556 n = 445 combined) cohorts. Proportions of non-lymphoma cells in the sample were inferred using the ESTIMATE algorithm. Read More

View Article and Full-Text PDF